Expertise in
10
conditions

Dr. Sunil Sharma

Oncology
University Hospital
2000 Circle Of Hope Dr, 
Salt Lake City, UT 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Expertise in
10
conditions
University Hospital
2000 Circle Of Hope Dr, 
Salt Lake City, UT 

Overview

Sunil Sharma is an Oncologist practicing medicine in Salt Lake City, Utah.

Dr. Sharma is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Familial Pancreatic Cancer, Ewing Sarcoma, Endoscopy, and Sleeve Gastrectomy.

He is actively involved in clinical research, co-authoring 323 peer reviewed articles and participating in 17 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in NV

Hospital Affiliations

Honorhealth Scottsdale Shea Medical Center
Honor Health John C. Lincoln Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 1 Less Insurance Carrier -

Locations

University Hospital
2000 Circle Of Hope Dr, Salt Lake City, UT 84112
Other Locations
Office
10510 N 92nd St Ste 200, Scottsdale, AZ 85258

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

An Open-Label, Multicenter, First-in-Human, Phase 1 Dose-Escalation and Multicohort Expansion Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
An Open-Label, Multicenter, First-in-Human, Phase 1 Dose-Escalation and Multicohort Expansion Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Enrollment Status: Recruiting
Publish Date: May 22, 2026
Intervention Type: Drug
Study Drugs: INBRX-109 Tetravalent DR5 Agonist Antibody, Carboplatin, Cisplatin, Pemetrexed, 5-Fluorouracil, Irinotecan
Study Phase: Phase 1
A Phase 1b Trial of the IRX-2 Regimen and Nivolumab in Patients With Advanced Hepatocellular Cancer (HCC)
A Phase 1b Trial of the IRX-2 Regimen and Nivolumab in Patients With Advanced Hepatocellular Cancer (HCC)
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2026
Intervention Type: Drug, Biological
Study Drugs: Cyclophosphamide, Cytokine-based Biologic Agent IRX-2, Nivolumab
Study Phase: Phase 1
Phase Ib Study of Gevokizumab in Combination With Standard of Care Anti-cancer Therapies in Patients With Metastatic Colorectal Cancer, Gastroesophageal Cancer and Renal Cell Carcinoma
Phase Ib Study of Gevokizumab in Combination With Standard of Care Anti-cancer Therapies in Patients With Metastatic Colorectal Cancer, Gastroesophageal Cancer and Renal Cell Carcinoma
Enrollment Status: Completed
Publish Date: April 01, 2026
Intervention Type: Drug
Study Drugs: Gevokizumab, Bevacizumab, Modified FOLFOX6, FOLFIRI, Ramucirumab, Paclitaxel, Cabozantinib
Study Phase: Phase 1
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)
Enrollment Status: Active_not_recruiting
Publish Date: October 28, 2025
Intervention Type: Drug
Study Drugs: TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel
Study Phase: Phase 1
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
Enrollment Status: Completed
Publish Date: August 14, 2025
Intervention Type: Drug
Study Drugs: INCAGN01876, Nivolumab, Ipilimumab
Study Phase: Phase 1/Phase 2
An Open-Label, Multicenter, Non-Randomized, Dose-Confirmation and Cohort-Expansion Phase 1b Study to Evaluate the Safety, Tolerability, and Anti-Tumor Activity of ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer
An Open-Label, Multicenter, Non-Randomized, Dose-Confirmation and Cohort-Expansion Phase 1b Study to Evaluate the Safety, Tolerability, and Anti-Tumor Activity of ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 29, 2025
Intervention Type: Drug
Study Drugs: ATP-128, BI-754091
Study Phase: Phase 1
Phase 1 Multicenter, Open-Label, Dose Escalation Study and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of STP705 Administered Intratumorally in Cholangiocarcinoma, Hepatocellular Carcinoma or Liver Metastases in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy
Phase 1 Multicenter, Open-Label, Dose Escalation Study and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of STP705 Administered Intratumorally in Cholangiocarcinoma, Hepatocellular Carcinoma or Liver Metastases in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy
Enrollment Status: Completed
Publish Date: March 19, 2024
Intervention Type: Drug
Study Drug: STP705
Study Phase: Phase 1
Phase 1 and Phase 2a, First-in-human Study of DRP-104, a Glutamine Antagonist, in Adult Patients With Advanced Solid Tumors
Phase 1 and Phase 2a, First-in-human Study of DRP-104, a Glutamine Antagonist, in Adult Patients With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: June 12, 2023
Intervention Type: Biological, Drug
Study Drugs: DRP-104, Atezolizumab
Study Phase: Phase 1/Phase 2
A Phase 1b/2 Trial of the IRX-2 Regimen and Pembrolizumab in Patients With Advanced Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
A Phase 1b/2 Trial of the IRX-2 Regimen and Pembrolizumab in Patients With Advanced Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
Enrollment Status: Completed
Publish Date: March 23, 2023
Intervention Type: Drug, Biological
Study Drugs: Cyclophosphamide, Cytokine-based Biologic Agent IRX-2, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Phase 1 Study of Subcutaneous Recombinant Human NIZ985 ((hetIL-15) (IL15/sIL-15Ra)) Alone and in Combination With PDR001 in Adults With Metastatic Cancers
A Phase 1 Study of Subcutaneous Recombinant Human NIZ985 ((hetIL-15) (IL15/sIL-15Ra)) Alone and in Combination With PDR001 in Adults With Metastatic Cancers
Enrollment Status: Terminated
Publish Date: March 03, 2023
Intervention Type: Drug
Study Phase: Phase 1
View 9 Less Clinical Trials

323 Total Publications

Advancing a Global Oral Health Research Agenda.
Advancing a Global Oral Health Research Agenda.
Journal: Journal of dental research
Published: June 16, 2026
Similar Doctors
Expertise in
17
conditions
Dr. Neeraj Agarwal
Oncology
Expertise in
17
conditions
Dr. Neeraj Agarwal
Oncology
Referral may be required

Huntsman Cancer Institute, Hematology-Oncology

1950 Circle Of Hope Dr, 
Salt Lake City, UT 
 (497.0 miles away)
801-585-0100
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Neeraj Agarwal is an Oncologist practicing medicine in Salt Lake City, Utah. Dr. Agarwal is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Renal Cell Carcinoma (RCC), Familial Prostate Cancer, Orchiectomy, and Tissue Biopsy. Dr. Agarwal is board certified in American Board Of Internal Medicine. Dr. Agarwal is currently accepting new patients.

Expertise in
16
conditions
Dr. Michael Pulsipher
Hematology | Oncology
Expertise in
16
conditions
Dr. Michael Pulsipher
Hematology | Oncology
Referral may be required

Pediatric Bone Marrow Transplant

100 N Mario Capecchi Dr, 
Salt Lake City, UT 
 (496.8 miles away)
801-662-4700
Languages Spoken:
English
See accepted insurances

Michael Pulsipher is a Hematologist and an Oncologist practicing medicine in Salt Lake City, Utah. Dr. Pulsipher is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Acute Lymphoblastic Leukemia (ALL), Graft Versus Host Disease (GvHD), Leukemia, Chronic Graft Versus Host Disease (cGvHD), and Bone Marrow Transplant. Dr. Pulsipher is board certified in American Board Of Pediatrics.

Expertise in
16
conditions
Dr. Ignacio Garrido
Oncology
Expertise in
16
conditions
Dr. Ignacio Garrido
Oncology
Referral may be required

Hematology-Oncology - Nielsen Rehabilitation Hospital

85 N Medical Dr, 
Salt Lake City, UT 
 (496.9 miles away)
801-585-0100
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ignacio Garrido is an Oncologist practicing medicine in Salt Lake City, Utah. Dr. Garrido is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Pancreatoblastoma, and Pancreatectomy. Dr. Garrido is board certified in American Board Of Internal Medicine. Dr. Garrido is currently accepting new patients.

Frequently Asked Questions about Dr. Sunil Sharma

How do I make an appointment with Dr. Sunil Sharma?

You can book an appointment with Dr. Sunil Sharma by calling their office at 801-587-5559. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Sunil Sharma a top-rated expert for Colorectal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Sunil Sharma is classified as an Distinguished expert for Colorectal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Sunil Sharma specialize in?

While Dr. Sunil Sharma is a Oncology, they have specific expertise in Colorectal Cancer, Familial Pancreatic Cancer, and Ewing Sarcoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Sunil Sharma participate in research or clinical trials?

Yes. Dr. Sunil Sharma has published 323 articles and abstracts on conditions like Colorectal Cancer. You can view a list of Dr. Sunil Sharma's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Sunil Sharma accept my insurance?

Dr. Sunil Sharma accepts most major insurance plans, including Aetna and CareFirst. We recommend calling the office directly at 801-587-5559 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sharma's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 45 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile